HeartBeat.bio Collaborates with Boehringer Ingelheim on Gene Therapies

HeartBeat.bio AG has formed a research partnership with Boehringer Ingelheim to develop gene therapies for inherited heart muscle disorders. This collaboration combines Boehringer Ingelheim's experience in gene therapy with HeartBeat.bio's Cardioid Drug Discovery Platform to address a need in cardiovascular health.

Inherited heart diseases are a leading cause of heart failure and sudden death, especially in younger individuals. In major markets like the US, EU, and Japan, about one million people suffer from these conditions, often facing limited treatment options.

HeartBeat.bio’s platform uses cardiac organoids to replicate heart disease features, allowing precise and rapid therapy testing. This collaboration builds on a strong relationship, with Boehringer Ingelheim contributing expertise and resources to advance HeartBeat.bio's platform.